Clinical trials have characterized the rates of GI bleeding between (DOACs and warfarin. However, there has been a lack of clinical trials comparing rates of GI bleeding between DOACs and mixed findings from real-world studies. This population-based study conducted in Iceland determined the incidence of GI bleeding using manual chart review for patients receiving apixaban, dabigatran, and rivaroxaban.

Read the Journal Scan